// App-Quantinova.ai

105.0 : Comparison of real-world treatment patterns, persistence, healthcare resource utilization (HRU) and costs between octreotide and lanreotide for the treatment of neuroendocrine tumors (NET).

Researchers

Presenter

  • Lynn Huynh

Principal Investigators

  • Beilei Cai

  • Camara Sharperson

  • Dominique Lejeune

  • Mei Sheng Duh

  • Michelle Kang Kim

Medical Centers

  • Analysis Group, Inc., Boston, MA

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Groupe d'analyse, Ltee, Montreal, QC, Canada

  • Mount Sinai School of Medicine, New York, NY

Locations

  • United States

  • Canada

Companies

  • Analysis Group, Inc.

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Neuroendocrine tumors

Biomarkers

  • N/A

Drug/Treatment

  • Lanreotide

  • Octreotide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved